Treatment to protect and / or recover sexual function of the cavernosal nerve (sexual potency) after radical prostatectomy

Tech ID: 22229 / UC Case 2010-964-0

Brief Description

It is estimated that 1 in 6 men will be diagnosed with prostate cancer in their lifetime. One of the consequences of removing the prostate for prostate cancer is a non-permanent injury of the cavernosal nerve during open radical prostatectomy (RP) or robot-assisted radical prostatectomy (RARP), which may result in post-operative sexual dysfunction. These sexual side effects can severely affect the quality of life for men and their loved ones.

Researchers at the University of California, Irvine have developed a new use for an existing compound that can be used to prevent, mitigate, or treat erectile dysfunction associated with prostate removal surgery.

Suggested uses

The compound may be used to treat erectile dysfunction in men who have undergone prostatectomy due to prostate cancer.

Patent Status

Country Type Number Dated Case
United States Of America Issued Patent 8,653,057 02/18/2014 2010-964


Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information


Sexual dysfunction, Erectile dysfunction, Prostate cancer

Categorized As

  • Institute for Innovation Logo
  • Institute for Innovation Logo

University of California, Irvine Invention Transfer Group
5141 California Avenue, Suite 200, Irvine,CA 92697-7700
Tel: 949.824.2683 | Fax: 949.824.3880 |

© 2012 - 2014, The Regents of the University of California
Terms of use | Privacy Notice